GlassScriptPhysician profile
Idella A Struk
NPI 1336218791
$6,030.93
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,895 · 2022: $2,476 · 2023: $1,592 · 2024: $68.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,808.70 | 2021-2022 | |
| Abbvie INC. | $588.78 | 2021-2023 | |
| Sk Life Science, INC. | $459.57 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $296.27 | 2022-2023 | |
| Neurelis, INC. | $284.04 | 2021-2023 | Valtoco |
| Lundbeck LLC | $242.27 | 2022-2023 | Vyepti |
| Horizon Therapeutics Plc | $177.28 | 2022-2023 | Uplizna |
| Neurocrine Biosciences, INC. | $174.94 | 2022-2023 | Ingrezza, Ongentys |
| Nevro Corp. | $163.44 | 2022 | |
| Argenx US, INC. | $156.68 | 2022-2023 | Vyvgart |
| Csl Behring | $115.78 | 2022-2023 | Hizentra |
| Lilly USA, LLC | $104.55 | 2022-2023 | Emgality, Amyvid |
| Banner Life Sciences, LLC | $101.79 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.64 | 2022 | |
| Acadia Pharmaceuticals INC | $93.50 | 2021-2024 | Nuplazid, Daybue |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Idella Struk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.